Earnings results for Avadel Pharmaceuticals PLC (NASDAQ:AVDL)
Avadel Pharmaceuticals plc is expected* to report earnings on 05/11/2020 before market open. The report will be for the fiscal Quarter ending Mar 2020. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.27. The reported EPS for the same quarter last year was $-0.35.
Avadel Pharmaceuticals last released its earnings results on March 12th, 2020. The reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.18. The firm had revenue of $11 million for the quarter, compared to analysts’ expectations of $11 million. Avadel Pharmaceuticals has generated ($0.89) earnings per share over the last year. Avadel Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Monday, May 11th, 2020. Avadel Pharmaceuticals will be holding an earnings conference call on Monday, May 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
Analyst Opinion on Avadel Pharmaceuticals PLC (NASDAQ:AVDL)
6 Wall Street analysts have issued ratings and price targets for Avadel Pharmaceuticals in the last 12 months. Their average twelve-month price target is $11.92, suggesting that the stock has a possible upside of 28.83%. The high price target for AVDL is $18.00 and the low price target for AVDL is $6.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Avadel Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $11.92, Avadel Pharmaceuticals has a potential upside of 28.8% from its current price of $9.25. Avadel Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.
Dividend Strength: Avadel Pharmaceuticals PLC (NASDAQ:AVDL)
Avadel Pharmaceuticals does not currently pay a dividend. Avadel Pharmaceuticals does not have a long track record of dividend growth.
Insiders buying/selling: Avadel Pharmaceuticals PLC (NASDAQ:AVDL)
In the past three months, Avadel Pharmaceuticals insiders have not sold or bought any company stock. Only 15.23% of the stock of Avadel Pharmaceuticals is held by insiders. 49.09% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Avadel Pharmaceuticals PLC (NASDAQ:AVDL
Earnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($0.76) to ($0.26) per share. The P/E ratio of Avadel Pharmaceuticals is -10.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Avadel Pharmaceuticals is -10.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
More latest stories: here